122 related articles for article (PubMed ID: 26454359)
1. Dupilumab: a milestone in the treatment of atopic dermatitis.
Tsianakas A; Ständer S
Lancet; 2016 Jan; 387(10013):4-5. PubMed ID: 26454359
[No Abstract] [Full Text] [Related]
2. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
3. Development of Sézary syndrome following the administration of dupilumab.
Tran J; Morris L; Vu A; Duvic M
Dermatol Online J; 2020 Apr; 26(4):. PubMed ID: 32621690
[TBL] [Abstract][Full Text] [Related]
4. Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.
Da J; Ali K; Lu K; Lou H; Qiu Y; Shan J; Wu L
Clin Exp Dermatol; 2022 Feb; 47(2):423-425. PubMed ID: 34482550
[No Abstract] [Full Text] [Related]
5. Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
Loret L; Ninclaus V; Dendooven A; Lapeere H; Kreps EO
Eur J Dermatol; 2021 Dec; 31(6):843-844. PubMed ID: 34933837
[No Abstract] [Full Text] [Related]
6. Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.
Szekely S; Vaccari D; Salmaso R; Belloni-Fortina A; Alaibac M
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):65-66. PubMed ID: 32490817
[No Abstract] [Full Text] [Related]
7. Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.
Charvet E; Bourrat E; Hickman G; Donadieu J; Bellanné-Chantelot C; Jachiet M; Bouaziz JD; Bagot M; Cassius C
Clin Exp Dermatol; 2021 Oct; 46(7):1334-1335. PubMed ID: 33864281
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
9. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Kurihara K; Fujiyama T; Tokura Y; Honda T
Eur J Dermatol; 2021 Oct; 31(5):658-660. PubMed ID: 34704949
[No Abstract] [Full Text] [Related]
10. Successful use of dupilumab for the treatment of atopic dermatitis on the genitals, a neglected anatomical site.
Paolino G; Sernicola A; Di Nicola MR; Foti A; Brianti P; Vaira F; Grieco T; Mercuri SR
Clin Exp Dermatol; 2022 Jan; 47(1):176-178. PubMed ID: 34398987
[TBL] [Abstract][Full Text] [Related]
11. Aarskog-Scott syndrome and atopic dermatitis successfully treated with dupilumab: a casual presentation?
Calabrese G; Licata G; Buononato D; Gambardella A; De Rosa A; Argenziano G
Clin Exp Dermatol; 2022 Feb; 47(2):452-453. PubMed ID: 34482546
[No Abstract] [Full Text] [Related]
12. Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI; Guttman-Yassky E; Gadkari A; Kuznik A; Mallya UG; Mastey V; Zhang H; Chen Z; Chen C; Korotzer A; Sierka D; Fenton MC; Kaur M; Jalbert JJ
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):40-45. PubMed ID: 32739313
[TBL] [Abstract][Full Text] [Related]
13. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A; Raponi F; Locatelli AG; Vezzoli P; Gambini DM; Di Mercurio M; Robustelli Test E; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e433-e434. PubMed ID: 32339362
[No Abstract] [Full Text] [Related]
14. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.
Sears AV; Woolf RT; Gribaleva E; Abdelrahman W; Robbie S; Menon B; Kirkham B; Smith CH; Pink AE
Br J Dermatol; 2021 Apr; 184(4):755-757. PubMed ID: 33107978
[No Abstract] [Full Text] [Related]
16. Successful and rapid clearance of severe, treatment-resistant atopic dermatitis with dupilumab in a 3-year-old.
Dakin H; Haas C
Dermatol Ther; 2020 Nov; 33(6):e14282. PubMed ID: 32888373
[No Abstract] [Full Text] [Related]
17. Interleukin-4 and anxiety in adults with atopic dermatitis.
Gray NA; Naude PJ; Esterhuizen TM; Khumalo NP; Stein DJ
Acta Neuropsychiatr; 2020 Oct; 32(5):271-273. PubMed ID: 32390578
[No Abstract] [Full Text] [Related]
18. Successful treatment of trichothiodystrophy with dupilumab.
Gruber R; Zschocke A; Zellner H; Schmuth M
Clin Exp Dermatol; 2021 Oct; 46(7):1381-1383. PubMed ID: 33955026
[TBL] [Abstract][Full Text] [Related]
19. Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
Arents BWM
Br J Dermatol; 2023 May; 188(6):694. PubMed ID: 37094084
[No Abstract] [Full Text] [Related]
20. Dupilumab as a novel therapy to treat adrenergic urticaria.
Goodman B; Jariwala S
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):205-206. PubMed ID: 32621993
[No Abstract] [Full Text] [Related]
[Next] [New Search]
